Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test.

Stephen Young, Stephanie Taylor, Catherine Cammarata, Celine Roger-Dalbert, Amanda Montano, Christen Griego-Fullbright, Cameron Burgard, Catherine Fernandez, Karen Eckert, Jeffrey C Andrews, Huimiao Ren, Joseph Allen, Ronald Ackerman, Devin Gary, Charles Cooper
doi: https://doi.org/10.1101/2020.09.01.20185777
Stephen Young
1 TriCore Reference Laboratories;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: steve.young@tricore.org
Stephanie Taylor
2 Louisiana State University Health Science Center;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: staylo2@lsuhsc.edu
Catherine Cammarata
2 Louisiana State University Health Science Center;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ccamma@lsuhsc.edu
Celine Roger-Dalbert
3 Becton, Dickinson and Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: celine_roger-dalbert@bd.com
Amanda Montano
4 Tricore Reference Laboratory;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: amanda.montano@tricore.org
Christen Griego-Fullbright
5 TriCore Reference Laboratory;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christen.griego-fullbright@tricore.org
Cameron Burgard
5 TriCore Reference Laboratory;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cameron.burgard@tricore.org
Catherine Fernandez
3 Becton, Dickinson and Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: catherine_fernandez@bd.com
Karen Eckert
3 Becton, Dickinson and Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: karen_eckert@bd.com
Jeffrey C Andrews
3 Becton, Dickinson and Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jeffrey.andrews@bd.com
Huimiao Ren
3 Becton, Dickinson and Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: huimiao_ren@bd.com
Joseph Allen
6 STAT Research;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: drallen@statresearch.net
Ronald Ackerman
7 Comprehensive Clinical Research, LLC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gobs@earthlink.net
Devin Gary
3 Becton, Dickinson and Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: devin.gary@bd.com
Charles Cooper
3 Becton, Dickinson and Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: charles_k_cooper@bd.com
  • Abstract
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives The clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 antigen (Veritor), a chromatographic immunoassay that detects the SARS-CoV-2 nucleocapsid antigen as a point-of-care test, was evaluated on nasal specimens from individuals with COVID-19 symptoms. Methods and Materials Two studies were completed to determine clinical performance. In the first study, nasal specimens and either nasopharyngeal or oropharyngeal specimens from 251 participants with COVID-19 symptoms (<=7 days from symptom onset [DSO]), >=18 years of age, were utilized to compare Veritor with the Lyra SARS-CoV-2 PCR Assay (Lyra). In the second study, nasal specimens from 361 participants with COVID-19 symptoms (<=5 DSO), >=18 years of age, were utilized to compare performance of Veritor to that of the Sofia 2 SARS Antigen FIA test (Sofia 2). Positive, negative, and overall percent agreement (PPA, NPA, and OPA, respectively) were the primary outcomes. Results In study 1, PPA for Veritor, compared to Lyra, ranged from 81.8%-87.5% for 0-1 through 0-6 DSO ranges. In study 2, Veritor had a PPA, NPA, and OPA of 97.4%, 98.1%, and 98.1%, respectively, with Sofia 2. Discordant analysis showed one Lyra positive missed by Veritor and five Lyra positives missed by Sofia 2; one Veritor positive result was negative by Lyra. Conclusions Veritor met FDA-EUA acceptance criteria for SARS-CoV-2 antigen testing (>=80% PPA point estimate) for the 0-5 and 0-6 DSO ranges. Veritor and Sofia 2 showed a high degree of agreement for SARS-CoV-2 detection. The Veritor test should facilitate rapid and reliable results for COVID-19 diagnosis utilizing easy-to-collect nasal swabs.

Competing Interest Statement

The authors disclose the following conflicts of interest: CRD, CF, KE, JCA, HR, and CKC are employees of Becton, Dickinson and Company; SY, None; CC, None; AM, None; CGF, None; CB, None; JA, None; RA, CEO and PI of Comprehensive Clinical Research LLC

Clinical Trial

Registration of this study at ClinicalTrials.gov was not obtained as it did not fulfill the applicable minimum medical device clinical trial requirement criteria as per the Food and Drug Administration Amendments Act. Specifically, this study did not assess health outcomes associated with the use of this assay.

Funding Statement

This study was funded by Becton, Dickinson and Company; BD Life Sciences-Integrated Diagnostics Solutions. Non-BD employee authors received research funds as part of this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Continuing review approval: Advarra IRB-CR00170042-Approval date: 3 Dec 2019 Continuing review Becton Dickinson - BDX-GSCP01, Becton Dickinson Program for Collection of BioSpecimens (Pro00015576) study 1 COVID approval notice: Advarra IRB-MOD00683499-Approval date: 29 May 2020 Becton Dickinson - BDX-GSCP01, Becton Dickinson Program for Collection of BioSpecimens (Pro00015576) Study 2 COVID approval notice: Advarra IRB-MOD00717838-Approval date: 13 Jul 2020 Becton Dickinson - BDX-GSCP01, Becton Dickinson Program for Collection of BioSpecimens (Pro00015576)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study should be requested from Dr. Charles K. Cooper. Contact Devin.Gary@bd.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 04, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test.
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test.
Stephen Young, Stephanie Taylor, Catherine Cammarata, Celine Roger-Dalbert, Amanda Montano, Christen Griego-Fullbright, Cameron Burgard, Catherine Fernandez, Karen Eckert, Jeffrey C Andrews, Huimiao Ren, Joseph Allen, Ronald Ackerman, Devin Gary, Charles Cooper
medRxiv 2020.09.01.20185777; doi: https://doi.org/10.1101/2020.09.01.20185777
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test.
Stephen Young, Stephanie Taylor, Catherine Cammarata, Celine Roger-Dalbert, Amanda Montano, Christen Griego-Fullbright, Cameron Burgard, Catherine Fernandez, Karen Eckert, Jeffrey C Andrews, Huimiao Ren, Joseph Allen, Ronald Ackerman, Devin Gary, Charles Cooper
medRxiv 2020.09.01.20185777; doi: https://doi.org/10.1101/2020.09.01.20185777

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (47)
  • Cardiovascular Medicine (416)
  • Dentistry and Oral Medicine (70)
  • Dermatology (49)
  • Emergency Medicine (146)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4875)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (678)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (633)
  • Health Policy (322)
  • Health Systems and Quality Improvement (208)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5361)
  • Intensive Care and Critical Care Medicine (332)
  • Medical Education (94)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (690)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (127)
  • Occupational and Environmental Health (209)
  • Oncology (443)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (17)
  • Pathology (130)
  • Pediatrics (196)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (782)
  • Public and Global Health (1823)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)